What is PTHS's remainder of 2026?

PTHS (PTHS) reported remainder of 2026 of $3.14M in Q1 2026.

PTHS PTHS Remainder of 2026

Remainder of 2026 at other companies

Zevra Therapeutics, Inc.ZVRA

——

HRO

HarrowHROW

——

Bausch + LombBLCO

——

Other financials

Income statement

See full

Revenue$10.9M—

Gross profit$9.2M—

Operating income-$13.1M-614%

Net income-$10.2M-420%

EPS (diluted)-$3.09+3.7%

Balance sheet

See full

Cash & equivalents$32.0M+24,250%

Total debt$29.6M—

Total equity$35.1M+937%

Total assets$145.4M+15,855%

Cash flow

See full

Operating cash flow-$13.1M-1,977%

CapEx$194.0K—

Free cash flow-$13.3M-2,008%

Valuation

See full

Market cap$98.22M+75.4%

Enterprise value$95.89M—

P/S3.6×—

Profitability

See full

Gross margin79.6%—

Operating margin-157.7%—

Net margin-186.2%—

FCF margin-60.8%—

Returns & leverage

See full

Return on equity-333.8%—

Debt / equity0.8×—

Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's remainder of 2026.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTHS's remainder of 2026?: PTHS (PTHS) reported remainder of 2026 of $3.14M in Q1 2026.